Cromos Pharma is pleased to share news about our latest project - an international double-blind placebo-controlled clinical trial of RPH-104 in acute ST-Elevation Myocardial Infarction (STEMI). The trial involving patients in the US and in Russia will investigate how a biologic RPH-104 developed by R-Pharm can reduce an acute inflammatory response after myocardial infarction and lead to improved outcomes for STEMI patients.
“This innovative study offers great hope for the better management of STEMI patients. By specifically inhibiting Interleukin-1 (IL-1) which plays a key role in the inflammatory response this drug may reduce further cardiac damage and improve outcomes”, says Dr Vlad Bogin, CEO of Cromos Pharma.
The trial began enrolling in early 2021 in the US and in Russia. Its sites in the US include some of the most prestigious medical institutions in the US: VCU School of Medicine and the Cleveland Clinic.
Read the article in the Journal of Translational Medicine co-authored by Dr Vlad Bogin about the study design and its rationale here
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking an estimated 17.9 million lives each year. Many of these deaths are premature, afflicting people under 70. Acute myocardial infarction or heart attack is the most prevalent form of CVD. STEMI is a very serious heart attack and is characterized by an acute inflammatory response following myocardial infarction causing high mortality.
Cromos Pharma has 15+ years of experience delivering fully integrated clinical research solutions in all aspects of clinical trials across a wide range of therapeutic areas. Find out more about how we can add value to your clinical program by emailing email@example.com.